Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BHC Stock Forecast 2026-2027
$4.99
Current Price
$1.86B
Market Cap
Buy 1
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to BHC Price Targets
+80.4%
To High Target of $9.00
+40.3%
To Median Target of $7.00
+20.2%
To Low Target of $6.00
BHC Price Momentum
-3.5%
1 Week Change
-7.9%
1 Month Change
-15.6%
1 Year Change
-28.2%
Year-to-Date Change
-42.6%
From 52W High of $8.69
+1.2%
From 52W Low of $4.93
📊 TOP ANALYST CALLS
Did BHC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Bausch Health is one of their latest high-conviction picks.
Latest BHC Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, BHC has a neutral consensus with a median price target of $7.00 (ranging from $6.00 to $9.00). The overall analyst rating is Buy (6.3/10). Currently trading at $4.99, the median forecast implies a 40.3% upside. This outlook is supported by 1 Buy, 7 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Douglas Miehm at RBC Capital, projecting a 80.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BHC Analyst Ratings
1
Buy
7
Hold
0
Sell
BHC Price Target Range
Low
$6.00
Average
$7.00
High
$9.00
Current: $4.99
Latest BHC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BHC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 27, 2026 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $9.00 |
| Feb 25, 2026 | Barclays | Equal-Weight | Maintains | $N/A | |
| Jan 7, 2026 | Truist Securities | Hold | Maintains | $N/A | |
| Dec 9, 2025 | Barclays | Equal-Weight | Initiates | $N/A | |
| May 2, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Feb 6, 2025 | Jefferies | Hold | Downgrade | $N/A | |
| Jan 30, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Nov 1, 2024 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Aug 2, 2024 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Aug 2, 2024 | Piper Sandler | Underweight | Downgrade | $N/A | |
| Jul 25, 2024 | Truist Securities | Hold | Maintains | $N/A | |
| Jul 10, 2024 | Raymond James | Market Perform | Initiates | $N/A | |
| Apr 23, 2024 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Apr 12, 2024 | RBC Capital | Sector Perform | Reiterates | $N/A | |
| Apr 5, 2024 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Feb 23, 2024 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Sep 20, 2023 | Jefferies | Buy | Upgrade | $N/A | |
| Jun 16, 2023 | TD Cowen | Market Perform | Downgrade | $N/A | |
| May 22, 2023 | Jefferies | Buy | Maintains | $N/A | |
| May 5, 2023 | RBC Capital | Sector Perform | Maintains | $N/A |
Bausch Health Companies Inc. (BHC) Competitors
The following stocks are similar to Bausch Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BHC
Bausch Health
mkt cap
1.89B
Bausch Health Companies Inc. (BHC) Financial Data
Bausch Health Companies Inc. has a market capitalization of $1.86B with a P/E ratio of 13.3x. The company generates $10.53B in trailing twelve-month revenue with a -11.5% profit margin.
Revenue growth is +11.7% quarter-over-quarter, while maintaining an operating margin of +20.6% and return on equity of +41.6%.
Valuation Metrics
Market Cap
$1.86B
Enterprise Value
$22.34B
P/E Ratio
13.3x
PEG Ratio
0.0x
Price/Sales
0.2x
Growth & Margins
Revenue Growth (YoY)
+11.7%
Gross Margin
+70.8%
Operating Margin
+20.6%
Net Margin
-11.5%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+69.7%
Current Ratio
1.3x
Debt/Equity
-19.2x
ROE
+41.6%
ROA
+5.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Bausch Health Companies Inc. (BHC) Business Model
About Bausch Health Companies Inc.
What They Do
Develops and markets pharmaceuticals and medical devices.
Business Model
The company generates revenue through a diverse range of branded and generic pharmaceuticals, over-the-counter products, and medical devices, focusing on chronic conditions and niche therapeutic areas. Its integrated approach combines research and development, manufacturing, and distribution, which supports its position in both specialty and cost-sensitive markets.
Additional Information
Bausch Health has a strong legacy from its acquisition of Bausch + Lomb, particularly in vision care and ophthalmic pharmaceuticals. The company aims for operational efficiency with a large workforce and demonstrates value-oriented characteristics, marked by low price-to-sales ratios and strategic capital allocation, while maintaining ongoing operating profitability.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
20,700
CEO
Mr. Thomas J. Appio
Country
Canada
IPO Year
2018
Website
www.bauschhealth.comBausch Health Companies Inc. (BHC) Latest News & Analysis
Latest News
Quick Summary
Bausch (BHC) reported earnings 30 days ago; investors should monitor upcoming developments and stock performance trends for future insights.
Why It Matters
Bausch's recent earnings report may influence stock performance, guiding investor sentiment and expectations for future growth or challenges. Monitor for potential volatility.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Thermage®, a non-invasive skin tightening brand from Bausch Health and Solta Medical, received the AAA Well-Known Trademark Certification in China, highlighting its market recognition.
Why It Matters
The AAA certification enhances Thermage's brand value and market position in China, potentially driving sales and investor confidence for Bausch Health and Solta Medical.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Bausch Health Companies Inc. (BHC) presented at the RBC Capital Markets Global Healthcare Conference 2026.
Why It Matters
Bausch Health's presentation at a major healthcare conference highlights its strategic direction and growth prospects, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Bausch Health Companies Inc. (BHC) presented at the Barclays 30th Annual Leveraged Finance Conference, discussing its financial strategies and outlook.
Why It Matters
Bausch Health's presentation at a major finance conference signals its strategic direction and potential growth opportunities, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Bausch Health Companies Inc. announced that all 10 director nominees, including Eiry W. Roberts, M.D., were elected at its Annual Meeting on May 19, 2026.
Why It Matters
The election of all director nominees, including a new appointee, signals stability and potential strategic shifts in Bausch Health's governance, influencing future performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Bausch + Lomb launched PreserVision AREDS3 eye vitamins in the U.S., combining AREDS2 nutrients with a B-vitamin complex to help reduce AMD progression.
Why It Matters
The launch of PreserVision AREDS3 strengthens Bausch + Lomb's product portfolio, potentially increasing market share and revenue in the eye health sector, which may positively impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About BHC Stock
What is Bausch Health Companies Inc.'s (BHC) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Bausch Health Companies Inc. (BHC) has a median price target of $7.00. The highest price target is $9.00 and the lowest is $6.00.
Is BHC stock a good investment in 2026?
According to current analyst ratings, BHC has 1 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.99. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BHC stock?
Wall Street analysts predict BHC stock could reach $7.00 in the next 12 months. This represents a 40.3% increase from the current price of $4.99. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bausch Health Companies Inc.'s business model?
The company generates revenue through a diverse range of branded and generic pharmaceuticals, over-the-counter products, and medical devices, focusing on chronic conditions and niche therapeutic areas. Its integrated approach combines research and development, manufacturing, and distribution, which supports its position in both specialty and cost-sensitive markets.
What is the highest forecasted price for BHC Bausch Health Companies Inc.?
The highest price target for BHC is $9.00 from Douglas Miehm at RBC Capital, which represents a 80.4% increase from the current price of $4.99.
What is the lowest forecasted price for BHC Bausch Health Companies Inc.?
The lowest price target for BHC is $6.00 from at , which represents a 20.2% increase from the current price of $4.99.
What is the overall BHC consensus from analysts for Bausch Health Companies Inc.?
The overall analyst consensus for BHC is neutral. Out of 2 Wall Street analysts, 1 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are BHC stock price projections?
Stock price projections, including those for Bausch Health Companies Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 11:18 AM UTC